Outcome of Assisted Reproduction Treatment in Women with Extremely Low Antimullerian Hormone (AMH) Levels

DOI: 10.4236/ojog.2014.415135   PDF   HTML   XML   3,777 Downloads   4,743 Views   Citations


Purpose: To evaluate age related ovarian response to controlled ovarian hyperstimulation, clinical pregnancy and ongoing pregnancy rates beyond 20 weeks in women undergoing assisted reproduction treatment (ART) with antimullerian hormone (AMH) levels of <5 pmol/l. Methods: Retrospective analysis of data from 63 women with AMH of <5 pmol/L who underwent their first assisted reproduction treatment (In-vitro fertilization, IVF and intracytoplasmic sperm injection, ICSI) cycle. Results were analyzed after dividing patients in two groups, group 1 included women of ≤38 years and group 2 > 38 years of age. Non parametric variables were expressed as median (Interquartile range) and compared by Kruskal-Wallis test. Categorical variables were expressed as numbers with proportions (%) and compared by Fisher’s exact test. Results: There was no statistical difference in body max index, level of antimullerian hormone (AMH), follicle stimulating hormone (FSH), dose of gonadotrophins used and cycles cancellation rate in two groups. Although number of oocytes retrieved (median 5), clinical pregnancy (18.4%) and ongoing pregnancy rate beyond 20 weeks (18.4%) was higher in group 1, there was no statistical difference between the two groups. There was one miscarriage in group 2. Conclusion: Women with extremely low-serum AMH levels can still have clinical pregnancy and ongoing pregnancies beyond 20 weeks after ART, though chances will be lower than women with normal ovarian reserve.

Share and Cite:

Hussain, M. , Cahill, D. , Akande, V. and Gordon, U. (2014) Outcome of Assisted Reproduction Treatment in Women with Extremely Low Antimullerian Hormone (AMH) Levels. Open Journal of Obstetrics and Gynecology, 4, 961-966. doi: 10.4236/ojog.2014.415135.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Faddy, M.J., Gosden, R.G., Gougeon, A., Richardson, S.J. and Nelson, J.F. (1992) Accelerated Disappearance of Ovarian Follicles in Mid-Life: Implications for Forecasting Menopause. Human Reproduction, 7, 1342-1346.
[2] Cahill, D.J., Prosser, C.J., Wardle, P.G., Ford, W.C.L. and Hull, M.G.R. (1994) Relative Influence of Serum Follicle Stimulating Hormone, Age, and Other Factors on Ovarian Response to Gonadotrophin Stimulation. BJOG: An International Journal of Obstetrics & Gynaecology, 101, 999-1002.
[3] Hull, M.G.R., Fleming, C.F., Hughes, A.O. and McDermott, A. (1996) The Age-Related Decline in Female Fecundity: A Quantitative Controlled Study of Implanting Capacity and Survival of Individual Embryos after in Vitro Fertilization. Fertility and Sterility, 65, 783-790.
[4] La Marca, A., Sighinolfi, G., Radi, D., Argento, C., Baraldi, E., Artenisio, A.C., Stabile, G. and Volpe, A. (2010) Anti-Müllerian Hormone (AMH) as a Predictive Marker in Assisted Reproductive Technology (ART). Human Reproduction Update, 16, 113-130. http://dx.doi.org/10.1093/humupd/dmp036
[5] Anderson, R.A., Nelson, S.M. and Wallace, W.H.B. (2012) Measuring Anti-Müllerian Hormone for the Assessment of Ovarian Reserve: When and for Whom Is It Indicated? Maturitas, 71, 28-33. http://dx.doi.org/10.1016/j.maturitas.2011.11.008
[6] Nelson, S.M., Yates, R.W. and Fleming, R. (2007) Serum Anti-Müllerian Hormone and FSH: Prediction of Live Birth and Extremes of Response in Stimulated Cycles—Implications for Individualization of Therapy. Human Reproduction, 22, 2414-2421. http://dx.doi.org/10.1093/humrep/dem204
[7] Nelson, S.M., Yates, R.W., Lyall, H., Jamieson, M., Traynor, I., Gaudoin, M., Mitchell, P., Ambrose, P. and Fleming, R. (2009) Anti-Müllerian Hormone-Based Approach to Controlled Ovarian Stimulation for Assisted Conception. Human Reproduction, 24, 867-875. http://dx.doi.org/10.1093/humrep/den480
[8] Nardo, L.G., Fleming, R., Howles, C.M., Bosch, E., Hamamah, S., Ubaldi, F.M., Hugues, J.N., Balen, A.H. and Nelson, S.M. (2011) Conventional Ovarian Stimulation No Longer Exists: Welcome to the Age of Individualized Ovarian Stimulation. Reproductive BioMedicine Online, 23, 141-148.
[9] Yates, A.P., Rustamov, O., Roberts, S.A., Lim, H.Y., Pimberton, P.W., Smith, A. and Nardo, L.G. (2011) Anti-Mullerian Hormone-Tailored Stimulation Protocols Improve Outcomes Whilst Reducing Adverse Effects and Costs of IVF. Human Reproduction, 26, 2353-2362.
[10] Steiner, A.Z., Herring, A.H., Kenser, J.S., et al. (2011) Antimullerian Hormone as Predictor of Natural Fecundability in Women Aged 30-42 Years. Obstetrics & Gynecology, 117, 798-804.
[11] Broekmans, F.J., Kwee, J., Hendriks, D.J., Mol, B.W. and Lambalk, C.B. (2006) A Systematic Review of Tests Predicting Ovarian Reserve and IVF Outcome. Human Reproduction Update, 12, 685-718. http://dx.doi.org/10.1093/humupd/dml034
[12] Bhide, P., Gudi, A., Shah, A., Timms, P., Grayson, K. and Homburg, R. (2013) Anti-Müllerian Hormone as a Predictor of Pregnancy Following IVF. Reproductive BioMedicine Online, 26, 247-252.
[13] Weghofer, A., Dietrich, W., Barad, D.H. and Gleicher, N. (2011) Live Birth Chances in Women with Extremely Low Serum Anti-Mullerian Hormones Levels. Human Reproduction, 26, 1905-1909. http://dx.doi.org/10.1093/humrep/der134
[14] Kailasam, C., Hunt, L., Ryder, I., Bhakri, I. and Gordon, U.D. (2008) Safety and Effectiveness of Diclofenac Sodium in Assisted Reproduction Treatment: A Randomized Prospective Double-Blind Study. Reproductive BioMedicine Online, 16, 724-729.
[15] Gleicher, N., Weghofer, A. and Barad, D.H. (2010) Antimullerian Hormone (AMH) Defines Independent of Age, Low versus Good Live Birth Chances in Women with Severely Diminished Ovarian Reserve. Fertility and Sterility, 94, 2824-2827. http://dx.doi.org/10.1016/j.fertnstert.2010.04.067
[16] Barad, D.H., Weghofer, A. and Gleicher, N. (2009) How Predictive of Basic Pregnancy Potential Are Extremely Low Levels of Anti-Mullerian Hormone (AMH). Fertility and Sterility, 92, 178-179.
[17] Kedem, A., Haas, J., Geva, L.L., Yerushalmi, G., Gilboa, Y., Kanety, H., Hanochi, M., Maman, E. and Hourvitz, A. (2013) Ongoing Pregnancy Rates in Women with Low and Extremely Low AMH Levels. A Multivariate Analysis of 769 Cycles. PLoS ONE, 8, e81629.
[18] Lukaszuk, K., Kunicki, M., Liss, J., Bednarowska, A. and Jakiel, G. (2014) Probability of Live Birth in Women with Extremely Low Anti-Müllerian Hormone Concentrations. Reproductive BioMedicine Online, 28, 64-69. http://dx.doi.org/10.1016/j.rbmo.2013.09.017
[19] Society for Assisted Reproductive Technology. IVF Success Rates, National Data Summary. http://www.sart.org/fram/detail.aspx?id=3893
[20] Coccia, M.E. and Rizzello, F. (2008) Ovarian Reserve. Annals of New York Academy of Sciences, 1127, 27-30. http://dx.doi.org/10.1196/annals.1434.011
[21] Check, J.R., Nazari, P., Check, M.L., Choe, J.K. and Liss, J.R. (2002) Prognosis Following in Vitro Fertilization-Embryo Transfer (IVF-ET) in Patients with Elevated Day 2 or 3 Serum Follicle Stimulating Hormone (FSH) Is Better in Younger vs Older Patients. Clinical Experimental Obstetrics Gynecology, 29, 42-44.
[22] Smeenk, J.M., Sweep, F.C., Zielhuis, G.A., et al. (2007) Antimullerian Hormone Predicts Ovarian Responsiveness, but Not Embryo Quality or Pregnancy, after in Vitro Fertilization or Intracytoplasmic Sperm Injection. Fertility and Sterility, 87, 223-226.
[23] Overbeek, A., Broekmans, F.J., Hehenkamp, W.J., Wijdeveld, M.E., van Disseldorp, J., van Dulmen-den, B.E. and Lambalk, C.B. (2012) Intra-Cycle Fluctuations of Anti-Müllerian Hormone in Normal Women with a Regular Cycle: A Reanalysis. Reproductive BioMedicine Online, 24, 664-669.
[24] Wunder, D.M., Bersinger, N.A., Yared, M., Kretschmer, R. and Birkhauser, M.H. (2008) Statistically Significant Changes of Antimullerian Hormone and Inhibin Levels during the Physiologic Menstrual Cycle in Reproductive Age Women. Fertility and Sterility, 89, 927-933.
[25] Buyuk, E., Seifer, D.B., Younger, J., Grazi, R.V. and Lieman, H. (2011) Random Anti-Müllerian Hormone (AMH) Is a Predictor of Ovarian Response in Women with Elevated Baseline Early Follicle-Stimulating Hormone Levels. Fertility and Sterility, 95, 2369-2372.
[26] Nelson, S.M. (2012) Chapter 25: The Patient with Poor Ovarian Reserve. In: Sharif, K. and Coomarasamy, A., Eds., Assisted Reproduction Techniques: Challenges and Management Options, Wiley-Blackwell, Oxford, 99-104.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.